Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150874 · ClinicalTrials.gov registry record · Early Phase 1
Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT04150874 is a Early Phase 1 study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 4 participants.
The verdict
NCT04150874, a Early Phase 1 study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the study is to find out if a study agent called Lumason® microbubbles may be helpful for people with lesions in the liver. It is possible it may help determine an early response to radioembolization and/or help demonstrate radiation toxicity to the surrounding liver.
Interventions
- DIAGNOSTIC_TEST Lumason®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2021-05-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04150874
The ClinicalTrials.gov registry entry for NCT04150874 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lumason® is the first listed.
NCT04150874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04150874 about?
NCT04150874 is a clinical study titled "Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE". The purpose of the study is to find out if a study agent called Lumason® microbubbles may be helpful for people with lesions in the liver. It is possible it may help determine an early response to radioembolization and/or help demonstrate radiation toxicity to the surrounding liver.
What is the current status of trial NCT04150874?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2020-02-19. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT04150874?
The interventions under investigation include: Lumason® (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04150874?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.